In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 5 ( 2022-5-23), p. e0268799-
Abstract:
Estrogen receptor-positive (ER+) breast cancer intrinsically confers satisfactory clinical outcomes in response to endocrine therapy. However, a significant proportion of patients with ER+ breast cancer do not respond well to this treatment. Therefore, to evaluate the effects of endocrine therapy, there is a need for identification of novel markers that can be used at the time of diagnosis for predicting clinical outcomes, especially for early-stage and late recurrence. Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter that has been proposed to be a viable prognostic marker for the luminal A and luminal B types of ER+ breast cancer. In the present study, we examined the possible association of SLC20A1 expression with tumor staging, endocrine therapy and chemotherapy in the luminal A and luminal B subtypes of breast cancer. In addition, we analyzed the relationship between SLC20A1 expression and late recurrence in patients with luminal A and luminal B breast cancer following endocrine therapy. We showed that patients with higher levels of SLC20A1 expression ( SLC20A1 high ) exhibited poorer clinical outcomes in those with tumor stage I luminal A breast cancer. In addition, this SLC20A1 high subgroup of patients exhibited less responses to endocrine therapy, specifically in those with the luminal A and luminal B subtypes of breast cancer. However, patients with SLC20A1 high showed good clinical outcomes following chemotherapy. Patients tested to be in the SLC20A1 high group at the time of diagnosis also showed a higher incidence of recurrence compared with those with lower expression levels of SLC20A1 , at 〉 15 years for luminal A breast cancer and at 10–15 years for luminal B breast cancer. Therefore, we conclude that SLC20A1 high can be used as a prognostic biomarker for predicting the efficacy of endocrine therapy and late recurrence for ER+ breast cancer.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0268799
DOI:
10.1371/journal.pone.0268799.g001
DOI:
10.1371/journal.pone.0268799.g002
DOI:
10.1371/journal.pone.0268799.g003
DOI:
10.1371/journal.pone.0268799.g004
DOI:
10.1371/journal.pone.0268799.g005
DOI:
10.1371/journal.pone.0268799.g006
DOI:
10.1371/journal.pone.0268799.g007
DOI:
10.1371/journal.pone.0268799.t001
DOI:
10.1371/journal.pone.0268799.t002
DOI:
10.1371/journal.pone.0268799.t003
DOI:
10.1371/journal.pone.0268799.t004
DOI:
10.1371/journal.pone.0268799.t005
DOI:
10.1371/journal.pone.0268799.s001
DOI:
10.1371/journal.pone.0268799.s002
DOI:
10.1371/journal.pone.0268799.s003
DOI:
10.1371/journal.pone.0268799.s004
DOI:
10.1371/journal.pone.0268799.s005
DOI:
10.1371/journal.pone.0268799.s006
DOI:
10.1371/journal.pone.0268799.s007
DOI:
10.1371/journal.pone.0268799.s008
DOI:
10.1371/journal.pone.0268799.s009
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Permalink